课题基金 / 基金详情

Dissecting the molecular pathways required for the generation and maintenance of induced myogenic progenitors (iMPCs) and assessing their potential for gene therapy

Dissecting the molecular pathways required for the generation and maintenance of induced myogenic progenitors (iMPCs) and assessing their potential for gene therapy
剖析诱导生肌祖细胞 (iMPC) 生成和维持所需的分子途径并评估其基因治疗潜力
批准号:
432895181
负责人:
Nikolaos Tsopoulidis, Ph.D.
金额:
$0.0万
依托单位国家:
德国
项目类别:
Research Fellowships
财政年份:
2019
资助国家:
德国
项目状态:
已结题
起止时间:
2018-12-31 至 2021-12-31

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Skeletal muscle is a regenerative tissue that is mostly comprised of differentiated myofibers responsible for contraction and thus movement. In addition,muscle contains a rare population of stem cells termed satellite cells, which are in a quiescent state under homeostatic conditions but undergo activation upon tissue injury. Once activated, satellite cells proliferate and form uncommitted myoblasts, which then differentiate and fuse with other myoblasts to regenerate damaged tissue. Remarkably, individual satellite cells have the capacity to produce myofibers and replenish the satellite cell niche when transplanted into damaged muscle. Satellite cells hold a great promise for muscle tissue generation. Although they can be explanted in culture for a limited period of time using growth factors and/or small compounds they cannot be expanded at numbers required for clinical use. Recently, the host lab has demonstrated the transdifferentiation of skin fibroblasts into myogenic stem-¬like cells that proliferate in culture and produce myofibers in vitro and in vivo. However, it is unclear to what extent these induced myogenic progenitor cells (iMPCs) resemble satellite cells. Also, the genetic that the “transdifferentiation” of fibroblasts to iMPCs underlie, remain elusive. Decoding these molecular mechanisms is key for understanding cell fate transitions beyond muscle stem cell generation and will be important for evaluating the iMPC’s potential for gene therapy approaches. •Objective 1. Are iMPC subsets molecularly and functionally equivalent to satellite cells? The first aim will be to compare gene expression and chromatin accessibility signatures between purified iMPCs and satellite cells using satellite cell reporter mice.•Objective 2. How do transcription factors and small molecules synergize to alter the epigenetic, gene expression and differentiation state mechanistically? Ectopic expression of the transcription factor MyoD alone is insufficient, while the expression of MyoD and treatment with a chemical cocktail is sufficient to establish a myogenic stem/progenitor-like state. We, therefore, aim to understand how exposure of skin fibroblasts to certain chemicals facilitates a chromatin state, that allows MyoD binding and thus a progenitor-¬like program.•Objective 3: Establish proof-of-principle evidence for the utility of iMPCs in gene and cell therapyWe hypothesize that the established iMPC culture system could be useful to study pathological myogenesis ex vivo. iMPCs should facilitate the introduction or correction of disease-associated mutations, which has therapeutic relevance. The goal of this aim is therefore to gather evidence that (i) iMPCs can be derived from dystrophic mouse models to study disease phenotypes, (ii) iMPCs are amenable to gene correction and (iii) corrected iMPCs differentiate into healthy myofibers upon transplantation.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
配子生成素GGN不同位点突变损伤分子伴侣BIP及HSP90B1功能导致精子形成障碍的发病机理
  • 批准号:
    82371616
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    姚晨成
  • 依托单位:
MYRF/SLC7A11调控施万细胞铁死亡在三叉神经痛脱髓鞘病变中的作用和分子机制研究
  • 批准号:
    82370981
  • 项目类别:
    面上项目
  • 资助金额:
    48.00万元
  • 批准年份:
    2023
  • 负责人:
    陈敏洁
  • 依托单位:
PET/MR多模态分子影像在阿尔茨海默病炎症机制中的研究
  • 批准号:
    82372073
  • 项目类别:
    面上项目
  • 资助金额:
    48.00万元
  • 批准年份:
    2023
  • 负责人:
    张淼
  • 依托单位:
GREB1突变介导雌激素受体信号通路导致深部浸润型子宫内膜异位症的分子遗传机制研究
  • 批准号:
    82371652
  • 项目类别:
    面上项目
  • 资助金额:
    45.00万元
  • 批准年份:
    2023
  • 负责人:
    刘开江
  • 依托单位: